Kinase Drug Screening-One-stop Service for Innovative Drug Non-clinical Evaluation-CRO Service

Kinases, as key members of the enzyme family, catalyze the transfer of the γ-phosphate group from ATP or GTP to specific amino acid residues on substrates, thereby inducing phosphorylation (Figures 1-2).

Figure 1. Generic catalytic domain of protein kinases depicting subdomain structure and function (Lahiry P, et al, Nat Rev Genet, 2010)

Figure 2. Phospho-signaling networks. The mechanism of phosphorylation regulation consists of kinases, phosphatases and their substrates phospho-binding proteins. (Ardito F, et al., Int J Mol Med. 2017)

Protein kinases are integral to cellular signaling pathways and they play a key role in the regulation of cell apoptosis, cell cycle progression, angiogenesis, and cellular metabolism. They serve as vital targets across a range of therapeutic areas, including cancer immunotherapy, inflammatory and cardiovascular disease. To date, the FDA has approved over 80 small-molecule kinase inhibitors (SMKIs), targeting 21 kinase families and covering approximately 20% of the known kinome.

Mutant kinases, often associated with acquired drug resistance, have become critical targets in drug discovery and development. Addressing mutation-driven resistance remains a critical unmet clinical need, making the comprehensive study of kinases and their mutants, along with the targeted screening and optimization of small-molecule inhibitors, a cornerstone in advancing cancer treatment.

Service Offerings

Genevoyager provides comprehensive preclinical kinase target development and drug screening solutions for scientists across academia, biotech, and pharma worldwide. Our capabilities are anchored by the proprietary One-Bac 4.0 system, a globally advanced platform for large-scale protein production, supported by robust process development and cGMP-grade manufacturing facilities. Our team has successfully developed over 50 highly bioactive kinases and related mutants, and continues to deliver customized solutions including kinase expression, biochemical assays, and in vitro/in vivo efficacy evaluation. By focusing on this pivotal enzyme family, we help accelerate drug discovery and enable therapeutic innovation - with the ultimate goal of improving human health and well-being.

Our Strengths

1、Leveraging our proprietary One-Bac 4.0 platform, we deliver high expression stability of kinase and cGMP-compliant protein production.

2、With deep expertise in the baculovirus-insect cell expression system, we offer flexible and proven solutions for kinase expression and process optimization.

3、Our extensive collection includes kinases across major families such as TK, TKL, STE, CMGC, AGC, PIKK, and PI3K, along with their associated mutants.

4、We provide robust in vitro and intracellular kinase activity assays, ensuring precise and consistent results to support your research.

List of in-stock kinases (selected)

Cat. No.	Kinase	Target Family	Structure	Tag/Position	Species	Expression System	Min. Order Quantity
KN2	AKT1	AKT	Full-length	N-GST-6His	human	sf9	5ug
KN51	AKT3	AKT	Catalytic domain	N-GST-6His	human	sf9	5ug
KN43	MER(MERTK)	Axl	Cytoplasmic domain	N-GST-6His	human	sf9	5ug
KN16	PIM1	CAMK	Full-length	N-GST-6His	human	sf9	5ug
KN17	PIM2	CAMK	Full-length	N-GST-6His	human	sf9	5ug
KN7	RAF1	CAMKL	Catalytic domain	N-GST-6His	human	sf9	5ug
KN3	CDK2	CDK	Full-length	N-GST-6His	human	sf9	5ug
KN8	CLK3	CMGC	Full-length	N-6His	human	sf9	5ug
KN9	MAPKAPK3	CMGC	Full-length	N-6His	human	sf9	5ug
KN10	MAPKAPK5	CMGC	Full-length	N-6His	human	sf9	5ug
KN11	CLK2	CMGC	Full-length	N-6HIS-GST	human	sf9	5ug
KN12	CDK7	CMGC	Full-length	N-GST-6His	human	sf9	5ug
KN13	DYRK1B	CMGC	Full-length	N-6HIS-GST	human	sf9	5ug
KN14	CLK1	CMGC	Full-length	N-GST-6His	human	sf9	5ug
KN15	CDK8	CMGC	Full-length	N-GST-6His	human	sf9	5ug
KN22	CDK4	CMGC	Full-length	N-6HIS-GST	human	sf9	5ug
KN23	CDK6	CMGC	Full-length	N-6HIS-GST	human	sf9	5ug
KN24	CDK6tb	CMGC	Full-length	N-6HIS-GST	human	sf9	5ug
KN49	CLK4	CMGC	Full-length	N-6HIS-GST	human	sf9	5ug
KN27	PIK3CB	Lipid kinase	Full-length	N-6HIS-GST	human	sf9	5ug
KN31	PIK3CG	Lipid kinase	Full-length	N-6His	human	sf9	5ug
KN18	PLK1	Other	Full-length	N-GST-6His	human	sf9	5ug
KN19	PLK3	Other	Catalytic domain	N-GST-6His	human	sf9	5ug
KN20	TTK	Other	Full-length	N-GST-6His	human	sf9	5ug
KN21	PLK2	Other	Full-length	N-GST-6His	human	sf9	5ug
KN44	PDGFRB	PDGFR	Cytoplasmic domain	N-6HIS-GST	human	sf9	5ug
KN40	BRK(PTK6)	Src	Full-length	N-GST-6His	human	sf9	5ug
KN41	LYNa	Src	Full-length	N-GST-6His	human	sf9	5ug
KN42	LYNb	Src	Full-length	N-GST-6His	human	sf9	5ug
KN1	MAP2K2	STE	Full-length	N-6HIS-GST	human	sf9	5ug
KN4	MAP2K6	STE	Full-length	N-GST-6His	human	sf9	5ug
KN5	MAP2K3	STE	Full-length	N-GST-6His	human	sf9	5ug
KN6	MAP2K5	STE	Full-length	N-GST-6His	human	sf9	5ug
KN50	MAP4K2	STE	Full-length	N-6HIS-GST	human	sf9	5ug
KN25	DDR1	TK	Cytoplasmic domain	N-6HIS-GST	human	sf9	5ug
KN26	SRC	TK	full length	N-GST-6His	human	sf9	5ug
KN28	FGFR1	TK	Cytoplasmic domain	N-GST-6His	human	sf9	5ug
KN29	AXL	TK	Cytoplasmic domain	N-GST-6His	human	sf9	5ug
KN30	SYK	TK	full length	N-GST-6His	human	sf9	5ug
KN34	BTK	TK	Full-length	N-GST-6His	human	sf9	5ug
KN35	BTK T316A	TK	Full-length	N-GST-6His	human	sf9	5ug
KN36	BTK M437R	TK	Full-length	N-GST-6His	human	sf9	5ug
KN37	BTK T474I	TK	Full-length	N-GST-6His	human	sf9	5ug
KN38	BTK T474S	TK	Full-length	N-GST-6His	human	sf9	5ug
KN39	BTK C481S	TK	Full-length	N-GST-6His	human	sf9	5ug
KN47	YES1(YES)	TK	Full-length	N-GST-6His	human	sf9	5ug
KN48	RET	TK	Cytoplasmic domain	N-GST-6His	human	sf9	5ug
KN78	EGFR	TK	Cytoplasmic domain	N-GST-6His	human	sf9	5ug
KN60	FGFR3	TK	Cytoplasmic domain	N-GST-6His	human	sf9	5ug
KN66	ALK	TK	Cytoplasmic domain	N-GST-6His	human	sf9	5ug
KN32	ACVR2B	TKL	Cytoplasmic domain	N-6HIS-GST	human	sf9	5ug
KN33	ACVRL1	TKL	Truncated	N-6HIS-GST	human	sf9	5ug
KN45	BMPR2	TKL	Cytoplasmic domain	N-6HIS-GST	human	sf9	5ug
KN46	IRAK4	TKL	Full-length	N-GST-6His	human	sf9	5ug

Contact us for more information.

Vector No.	Protein	Molecular Weight/KDa
PE333	GST-6His-HRV 3C site-ALK	70.459
PE334	GST-6His-HRV 3C site-FGFR3	73.934
PE335	GST-6His-HRV 3C site-EGFR	89.171

CRO Service

Kinase Drug Screening

Service Offerings

Our Strengths

List of in-stock kinases (selected)

Application Cases

Case Studies

More Content of Interest

CDMO Service

TECHNOLOGY PLATFORM

Case Studies：